Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Evaluating the Efficacy and Safety of HTD1801 in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

NCT06353347 is registered in ClinicalTrials.gov with Shenzhen HighTide Biopharmaceutical Ltd. as lead sponsor.

NCT NCT06353347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06353347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Evaluating the Efficacy and Safety of HTD1801 in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Lead sponsor
Shenzhen HighTide Biopharmaceutical Ltd.
Phase
Phase 3
Overall status
Completed
Start date
November 13, 2023
Completion date
July 30, 2025
Enrollment
551 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus